Cash Flow Statement

Amortization Amortization Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

ADC Therapeutics (ADCT) Deferred Taxes (2022 - 2023)

ADC Therapeutics has reported Deferred Taxes over the past 2 years, most recently at $42.9 million for Q4 2023.

Quarterly results put Deferred Taxes at $42.9 million for Q4 2023, up 2756.05% from a year ago — trailing twelve months through Sep 2024 was $42.9 million (up 681.98% YoY), and the annual figure for FY2023 was $37.1 million, up 2388.96%.
Deferred Taxes reached $42.9 million in Q4 2023 per ADCT's latest filing, up from -$578000.0 in the prior quarter.
Across five years, Deferred Taxes topped out at $42.9 million in Q4 2023 and bottomed at -$5.1 million in Q2 2023.